Ipsen announces new Vice President of Corporate External Communications
September 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen
French biopharmaceutical group Ipsen has announced that Dr Ian Weatherhead has taken up the position of Vice President, Corporate External …
Alzheimer’s disease: Fighting back against a growing threat
September 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's UK, dementia, life sciences, pharma
September marks Alzheimer’s Awareness Month, a crucial calendar period as the global threat of the disease slowly grows. To mark …
Mental health crisis as UK struggles with number of psychiatrists
September 11, 2017Business Services, Medical Communications, Sales and Marketing NHS, biotech, drugs, pharma, pharmaceutical, psychiatry
Research undertaken by the Royal College of Psychiatrists using data from NHS Digital has found that the number of psychiatrists …
Lilly’s Cyramza combo boasts strong results in bladder cancer
September 11, 2017Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma
Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …
Melanoma treatment: Novartis posts success, Roche stumbles
September 11, 2017Research and Development, Sales and Marketing Novartis, Roche, biotech, drugs, melanoma, pharma, pharmaceutical
In a perfect example of the competitive nature of the pharmaceutical industry, just as one company posted success in one …
AstraZeneca’s Tagrisso beats standard of care in halting NSCLC
September 11, 2017Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical
AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …
Teva finally announces successful CEO appointment
September 11, 2017Medical Communications, Sales and Marketing Lundbeck, Teva, biotech, drugs, pharma, pharmaceutical
Teva has announced that its protracted search for a new CEO has finally come to end, as it revealed the …
Casebia Therapeutics bolsters leadership by bringing in two new faces
September 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, CRISPR Therapeutics, Casebia Therapeutics, biotech, drugs, pharma, pharmaceutical
Casebia therapeutics, a joint venture between Bayer and CRISPR Therapeutics, has moved to strengthen its leadership team by bringing in …
Balancing the R&D equation: Measuring the return from pharmaceutical innovation
September 8, 2017Medical Communications, Research and Development
Following Deloitte’s anaylsis of the return on R&D spend by biopharmaceutical companies, this report reveals the key difficulties faced, as …
Top Ten most popular articles on Pharmafile.com this week
September 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
This week saw a number of hard-hitting stories hit the headlines that are sure to have resonant consequences. Following the …
Aspirin may be a cost-effective alternative to fillings
September 8, 2017Medical Communications, Research and Development aspirin, biotech, dentist, drugs, pharma, pharmaceutical, tooth decay
Researchers from Queen University, Belfast, have discovered that aspirin may be able to reverse the effects of tooth decay. In …
Lily announces massive staff cuts of 3,500 to “streamline business”
September 8, 2017Manufacturing and Production, Medical Communications, Sales and Marketing
In a drastic bid to “streamline business, invest in new medicines and drive”, Eli Lilly has announced major staff cuts …
BMS’ Opdivo gets a potential first-line boost in kidney cancer
September 8, 2017Medical Communications, Research and Development Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has announced results from a Phase 3 trial showing that patients treated with Opdivo alongside Yervoy in patients …
Antidepressants polluting rivers building up in brains of fish
September 7, 2017Medical Communications antidepressants, biotech, drugs, pharma, pharmaceutical
A study of ecosystem of the Niagara River has discovered that antidepressants are building up in the brains of fish. …
Booklet labels or Just-In-Time labelling: A question of standards
September 7, 2017Business Services, Manufacturing and Production Faubel, Labelling, packaging
Pharmaceutical companies are multiplying their efforts to establish just-in-time labeling. For Anthony Morrow, Business Development Manager Northern Europe at Faubel, …
High demands: Requirements on the labelling of pharmaceutical products are growing continuously
September 7, 2017Business Services, Manufacturing and Production Faubel, Labelling
There are numerous criteria to be met by label manufacturers. In this context, topics such as patient compliance and smart …
Vertex Pharma bring in new CFO, shares rise
September 7, 2017Ironwood Pharmaceuticals, Vertex pharmaceuticals, biotech, drugs, pharma, pharmaceutical
Vertex Pharmaceuticals announced the appointment of J&J veteran, Tom Graney, as Senior Vice President and Chief Financial Officer. Graney will …
Spotting Leukaemia
September 7, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, leukaemia, pharma, pharmaceutical
Leukaemia is a household name, but how much do we really understand about it? Not enough, says Bethany Torr, Campaigns …
New ‘pen’ device identifies cancerous tissue in just ten seconds
September 7, 2017Research and Development Cancer, University of Texas, digital, medicine, pharma, pharmaceutical, tumour
Scientists at the Baylor College of Medicine, University of Texas have developed a device which they claim can identify cancerous …
BMS hit by clinical trial hold from FDA
September 7, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, immunotherapy, opdivo, pharma, pharmaceutical
The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
